Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Despite an increasingly strident outcry against drug prices in the United States, manufacturers likely face an evolution in the reimbursement landscape, rather than a revolution.
The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval.
Although a US law mandating disclosure of GM ingredients provides food companies with a way out of the labeling rabbit hole, appeasing the anti-GM movement will likely backfire.
Nature Biotechnology will now publish all computational biology papers in its research section, a decision that reflects an ongoing need to break down silos surrounding mathematical, computational and basic biology.